E3泛素连接酶CUL2在宫颈癌中的研究进展

doi:10.12280/gjfckx.20200596

摘要/Abstract

摘要：

泛素化是蛋白质翻译后调控的重要途径。作为体内最大的 E3 泛素连接酶家族,Cullin-Ring类E3泛素连接酶广泛参与调控机体内细胞周期蛋白和转录因子的降解。其中,CUL2作为骨架分子形成CUL2泛素连接酶复合物,在希佩尔-林道（von Hippel-Lindau, VHL）肿瘤抑制因子相关受体底物的泛素化降解中发挥重要的作用。目前,研究发现CUL2普遍参与肿瘤血管生成、细胞动力、免疫逃逸、细胞增殖及等肿瘤恶变机制的调控。综述CUL2在肿瘤发生中的作用机制及其与宫颈癌的关系,旨在为宫颈癌的诊断和治疗提供新的作用靶点。

关键词: 宫颈肿瘤, 癌, 泛素蛋白连接酶类, 泛素化蛋白, 泛素化, 脑视网膜血管瘤抑制蛋白质

Abstract:

Ubiquitin is an important way of post-translational regulation of proteins. As the largest E3 ubiquitin ligase family in vivo, Cullin-Ring E3 ubiquitin ligases are widely involved in regulating the degradation of cyclins and transcription factors in vivo. CUL2, as a skeleton molecule, forms the CUL2 ubiquitin ligase complex, which plays an important role in the ubiquitination degradation of von Hippel-Lindau (VHL) tumor suppressor related receptor substrates. At present, studies have found that CUL2 is generally involved in the regulation of tumor malignant transformation mechanisms such as tumor angiogenesis, cell dynamics, immune escape, cell proliferation, and epithelial mesenchymal transition. In this paper, the mechanism of CUL2 in carcinogenesis and its relationship with cervical cancer are reviewed, aiming to provide a new target for diagnosis and treatment of cervical cancer.

Key words: Uterine cervical neoplasms, Carcinoma, Ubiquitin-protein ligases, Ubiquitinated proteins, Ubiquitination, Von hippel-lindau tumor suppressor protein

张宏蕾, 赵卫红. E3泛素连接酶CUL2在宫颈癌中的研究进展[J]. 国际妇产科学杂志, 2021, 48(2): 121-125.

ZHANG Hong-lei, ZHAO Wei-hong. Research Progress of E3 Ubiquitin Ligase CUL2 in Cervical Cancer[J]. Journal of International Obstetrics and Gynecology, 2021, 48(2): 121-125.

参考文献 37

[1]	Deshaies RJ, Pierce NW. Transfer of ubiquitin protein caught in the act[J]. Nature, 2020,578(7795):372-373. doi: 10.1038/d41586-020-00325-9. doi: 10.1038/d41586-020-00325-9 pmid: 32066917
[2]	Scott DC, Kleiger G. Regulation of Cullin-RING E3 ligase dynamics by Inositol hexakisphosphate[J]. Proc Natl Acad Sci U S A, 2020,117(12):6292-6294. doi: 10.1073/pnas.2001683117. pmid: 32156730
[3]	Liu Y, Tan X. Viral Manipulations of the Cullin-RING Ubiquitin Ligases[J]. Adv Exp Med Biol, 2020,1217:99-110. doi: 10.1007/978-981-15-1025-0_7. doi: 10.1007/978-981-15-1025-0_7 pmid: 31898224
[4]	Shafique S, Ali W, Kanwal S, et al. Structural basis for Cullins and RING component inhibition: Targeting E3 ubiquitin pathway conductors for cancer therapeutics[J]. Int J Biol Macromol, 2018,106:532-543. doi: 10.1016/j.ijbiomac.2017.08.047. doi: 10.1016/j.ijbiomac.2017.08.047 pmid: 28802844
[5]	Nguyen HC, Yang H, Fribourgh JL, et al. Insights into Cullin-RING E3 ubiquitin ligase recruitment: structure of the VHL-EloBC-Cul2 complex[J]. Structure, 2015,23(3):441-449. doi: 10.1016/j.str.2014.12.014. pmid: 25661653
[6]	Scott DC, Rhee DY, Duda DM, et al. Two Distinct Types of E3 Ligases Work in Unison to Regulate Substrate Ubiquitylation[J]. Cell, 2016, 166(5): 1198-1214.e24. doi: 10.1016/j.cell.2016.07.027. doi: 10.1016/j.cell.2016.07.027 pmid: 27565346
[7]	Mirabello L, Yeager M, Yu K, et al. HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis[J]. Cell, 2017, 170(6): 1164-1174.e6. doi: 10.1016/j.cell.2017.08.001. doi: 10.1016/j.cell.2017.08.001 pmid: 28886384
[8]	Carrillo-Beltrán D, Muñoz JP, Guerrero-Vásquez N, et al. Human Papillomavirus 16 E7 Promotes EGFR/PI3K/AKT1/NRF2 Signaling Pathway Contributing to PIR/NF-κB Activation in Oral Cancer Cells[J]. Cancers(Basel), 2020,12(7):1904. doi: 10.3390/cancers12071904.
[9]	Balasubramaniam SD, Balakrishnan V, Oon CE, et al. Key Molecular Events in Cervical Cancer Development[J]. Medicina (Kaunas), 2019,55(7):384. doi: 10.3390/medicina55070384.
[10]	Chan AB, Huber AL, Lamia KA. Cryptochromes modulate E2F family transcription factors[J]. Sci Rep, 2020,10(1):4077. doi: 10.1038/s41598-020-61087-y. pmid: 32139766
[11]	Huh K, Zhou X, Hayakawa H, et al. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor[J]. J Virol, 2007,81(18):9737-9747. doi: 10.1128/JVI.00881-07. doi: 10.1128/JVI.00881-07 pmid: 17609271
[12]	Xu J, Fang Y, Wang X, et al. CUL2 overexpression driven by CUL2/E2F1/miR-424 regulatory loop promotes HPV16 E7 induced cervical carcinogenesis[J]. Oncotarget, 2016,7(21):31520-31533. doi: 10.18632/oncotarget.9127. doi: 10.18632/oncotarget.9127 pmid: 27153550
[13]	Zhao W, Liu Y, Zhang L, et al. MicroRNA-154-5p regulates the HPV16 E7-pRb pathway in Cervical Carcinogenesis by targeting CUL2[J]. J Cancer, 2020,11(18):5379-5389. doi: 10.7150/jca.45871. doi: 10.7150/jca.45871 pmid: 32742484
[14]	Westrich JA, Warren CJ, Klausner MJ, et al. Human Papillomavirus 16 E7 Stabilizes APOBEC3A Protein by Inhibiting Cullin 2-Dependent Protein Degradation[J]. J Virol, 2018,92(7):e01318-17. doi: 10.1128/JVI.01318-17. doi: 10.1128/JVI.01318-17 pmid: 29367246
[15]	Smith NJ, Fenton TR. The APOBEC3 genes and their role in cancer: insights from human papillomavirus[J]. J Mol Endocrinol, 2019,62(4):R269-269R287. doi: 10.1530/JME-19-0011. doi: 10.1530/JME-19-0011 pmid: 30870810
[16]	Diamond CP, Im J, Button EA, et al. AID, APOBEC3A and APOBEC3B efficiently deaminate deoxycytidines neighboring DNA damage induced by oxidation or alkylation[J]. Biochim Biophys Acta Gen Subj, 2019,1863(11):129415. doi: 10.1016/j.bbagen.2019.129415. doi: 10.1016/j.bbagen.2019.129415 pmid: 31404619
[17]	Barontini M, Dahia PL. VHL disease[J]. Best Pract Res Clin Endocrinol Metab, 2010,24(3):401-413. doi: 10.1016/j.beem.2010.01.002. doi: 10.1016/j.beem.2010.01.002 pmid: 20833332
[18]	Hsieh JJ, Le VH, Oyama T, et al. Chromosome 3p Loss-Orchestrated VHL, HIF, Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma[J]. J Clin Oncol, 2018,36(36):JCO2018792549. doi: 10.1200/JCO.2018.79.2549. doi: 10.1200/JCO.2018.79.2341 pmid: 30372390
[19]	Cai L, Wang W, Li X, et al. MicroRNA-21-5p induces the metastatic phenotype of human cervical carcinoma cells in vitro by targeting the von Hippel-Lindau tumor suppressor[J]. Oncol Lett, 2018,15(4):5213-5219. doi: 10.3892/ol.2018.7937. doi: 10.3892/ol.2018.7937 pmid: 29552160
[20]	Guo Y, Meng X, Ma J, et al. Human papillomavirus 16 E6 contributes HIF-1α induced Warburg effect by attenuating the VHL-HIF-1α interaction[J]. Int J Mol Sci, 2014,15(5):7974-7986. doi: 10.3390/ijms15057974. doi: 10.3390/ijms15057974 pmid: 24810689
[21]	Liu X, Zurlo G, Zhang Q. The Roles of Cullin-2 E3 Ubiquitin Ligase Complex in Cancer[J]. Adv Exp Med Biol, 2020,1217:173-186. doi: 10.1007/978-981-15-1025-0_11. doi: 10.1007/978-981-15-1025-0_11 pmid: 31898228
[22]	Dasgupta SK, Thiagarajan P. Cofilin-1-induced actin reorganization in stored platelets[J]. Transfusion, 2020,60(4):806-814. doi: 10.1111/trf.15747. doi: 10.1111/trf.15747 pmid: 32159862
[23]	左玉, 李庆伟, 李莹莹. 丝切蛋白-1作为肿瘤治疗生物标记分子的作用机制[J]. 中国生物化学与分子生物学报, 2018,34(9):921-926. doi: 10.13865/j.cnki.cjbmb.2018.09.02.
[24]	Costessi A, Mahrour N, Sharma V, et al. The human EKC/KEOPS complex is recruited to Cullin2 ubiquitin ligases by the human tumour antigen PRAME[J]. PLoS One, 2012,7(8):e42822. doi: 10.1371/journal.pone.0042822. doi: 10.1371/journal.pone.0042822 pmid: 22912744
[25]	Costessi A, Mahrour N, Tijchon E, et al. The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters[J]. EMBO J, 2011,30(18):3786-3798. doi: 10.1038/emboj.2011.262. pmid: 21822215
[26]	Jiang Y, Cheng W, Li L, et al. Effective targeting of the ubiquitin-like modifier NEDD8 for lung adenocarcinoma treatment[J]. Cell Biol Toxicol, 2020,36(4):349-364. doi: 10.1007/s10565-019-09503-6. doi: 10.1007/s10565-019-09503-6 pmid: 31907687
[27]	Schwechheimer C. NEDD8-its role in the regulation of Cullin-RING ligases[J]. Curr Opin Plant Biol, 2018,45(Pt A):112-119. doi: 10.1016/j.pbi.2018.05.017. doi: 10.1016/j.pbi.2018.05.017 pmid: 29909289
[28]	Aubry A, Yu T, Bremner R. Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy[J]. Cell Death Discov, 2020,6:2. doi: 10.1038/s41420-020-0237-8. doi: 10.1038/s41420-020-0237-8 pmid: 32123578
[29]	Zhou L, Jia L. Targeting Protein Neddylation for Cancer Therapy[J]. Adv Exp Med Biol, 2020,1217:297-315. doi: 10.1007/978-981-15-1025-0_18. doi: 10.1007/978-981-15-1025-0_18 pmid: 31898235
[30]	Xu J, Li L, Yu G, et al. The neddylation-cullin 2-RBX1 E3 ligase axis targets tumor suppressor RhoB for degradation in liver cancer[J]. Mol Cell Proteomics, 2015,14(3):499-509. doi: 10.1074/mcp.M114.045211. doi: 10.1074/mcp.M114.045211 pmid: 25540389
[31]	Meng J, Chen S, Han JX, et al. Twist1 Regulates Vimentin through Cul2 Circular RNA to Promote EMT in Hepatocellular Carcinoma[J]. Cancer Res, 2018,78(15):4150-4162. doi: 10.1158/0008-5472.CAN-17-3009. doi: 10.1158/0008-5472.CAN-17-3009 pmid: 29844124
[32]	Lei M, Zheng G, Ning Q, et al. Translation and functional roles of circular RNAs in human cancer[J]. Mol Cancer, 2020,19(1):30. doi: 10.1186/s12943-020-1135-7. pmid: 32059672
[33]	汪雯雯, 栗妍, 陶涛, 等. TWIST介导的上皮-间质转化与宫颈癌发生发展相关性的研究[J]. 中华肿瘤防治杂志, 2011,18(22):1741-1745.
[34]	Babion I, Jaspers A, van Splunter AP, et al. miR-9-5p Exerts a Dual Role in Cervical Cancer and Targets Transcription Factor TWIST1[J]. Cells, 2019,9(1):65. doi: 10.3390/cells9010065. doi: 10.3390/cells9010065
[35]	Choi CH, Lee KM, Choi JJ, et al. Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer[J]. Cancer Lett, 2007,255(1):26-33. doi: 10.1016/j.canlet.2007.03.015. pmid: 17467893
[36]	Hwang J, Min BH, Jang J, et al. MicroRNA Expression Profiles in Gastric Carcinogenesis[J]. Sci Rep, 2018,8(1):14393. doi: 10.1038/s41598-018-32782-8. doi: 10.1038/s41598-018-32782-8 pmid: 30258124
[37]	Wang M, Zhang R, Zhang S, et al. MicroRNA-574-3p regulates epithelial mesenchymal transition and cisplatin resistance via targeting ZEB1 in human gastric carcinoma cells[J]. Gene, 2019,700:110-119. doi: 10.1016/j.gene.2019.03.043. doi: 10.1016/j.gene.2019.03.043 pmid: 30917930